Improving Functional Outcomes in Localized RCC
By Steven Campbell, MD, PhD - Last Updated: February 18, 2023Steven Campbell, MD, PhD, Professor of Surgery, Cleveland Clinic Glickman Urological and Kidney Institute, overviews the surgical options available for patients with localized renal cell carcinoma as well as how the field figures to evolve within the next few years.
Post Tags:ASCO GU 2023-Renal Cell Carcinoma
Related Posts
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
670 Madison Ave.
Manalapan, NJ 07726